Zogenix (ZGNX) Stock Analysis

What Zogenix does

Zogenix, Inc. is a biopharmaceutical company dedicated to the discovery, development, and commercialization of therapies for rare diseases within the United States, striving to profoundly improve the quality of life for affected patients and their families. Their flagship product candidate, Fintepla, a low-dose fenfluramine, is currently undergoing Phase III clinical evaluation for the management of seizures associated with Dravet syndrome and Lennox-Gastaut syndrome. Additionally, Fintepla is progressing through Phase II trials to address other less common epileptic syndromes and disorders. Another key pipeline asset is MT1621, an investigational treatment targeting thymidine kinase 2 deficiency, a severe genetic disorder. Zogenix, Inc. has established a collaboration with Tevard Biosciences focused on the research, development, and eventual commercialization of pioneering gene therapies for Dravet Syndrome and other inherited epilepsies. Established in 2006, the company was initially known as SJ2 Therapeutics, Inc. before rebranding as Zogenix, Inc. in August of the same year. Its corporate headquarters are situated in Emeryville, California.

Key metrics

ETFs linked to ZGNX

Broad-market and Healthcare sector ETFs an investor holding Zogenix is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how ZGNX fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Zogenix?

Zogenix trades under the ticker ZGNX on NASDAQ.

Which exchange is ZGNX listed on?

ZGNX is listed on NASDAQ.

What sector does Zogenix operate in?

Zogenix is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze ZGNX in a portfolio?

PortView shows ZGNX's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.